Add to ORKGSubchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces behavioral abnormalities in rodents which are considered a reliable pharmacological model of neurocognitive deficits in schizophrenia. Alterations in prefrontal neuronal firing after acute PCP administration have been observed, however enduring changes in prefrontal activity after subchronic PCP treatment have not been studied. To address this we have recorded cortical oscillations and unit responses in putative cortical pyramidal cells in subchronic PCP-treated rats (2mg/kg twice daily for 7 days) under urethane anesthesia. We found that this regimen reduced theta oscillations in the medial prefrontal cortex. It further produced abnormal corti...
Repeated exposure of rats to the psychotomimetic drug phen-cyclidine (PCP) markedly increased the re...
Antagonists of N-methyl-D-aspartate receptors (NMDAR) have psychotomimetic effects in humans and are...
Non-competitive antagonists of the N-methyl-d-aspartate receptor (NMDA) such as phencyclidine (PCP) ...
AbstractSubchronic treatment with the N-methyl-d-aspartate (NMDA) antagonist phencyclidine (PCP) pro...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Rationale N-methyl-D-aspartate receptor (NMDA-R) hypofunction has been proposed to account for the p...
Phencyclidine (PCP) is a psychotomimetic drug that elicits schizo-phrenia-like symptoms in healthy p...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
We have previously demonstrated that subchronic (five daily administrations of 2.6 mg/kg PCP) and ch...
Impaired ability to shift perceptual attentional set forms a core feature of schizophrenic illness a...
Rationale:Impaired ability to shift perceptual attentional set forms a core feature of schizophrenic...
The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamoc...
Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia...
<div><p>Antagonists of N-methyl-D-aspartate receptors (NMDAR) have psychotomimetic effects in humans...
Working memory impairment is a hallmark feature of schizophrenia and is thought be caused by dysfunc...
Repeated exposure of rats to the psychotomimetic drug phen-cyclidine (PCP) markedly increased the re...
Antagonists of N-methyl-D-aspartate receptors (NMDAR) have psychotomimetic effects in humans and are...
Non-competitive antagonists of the N-methyl-d-aspartate receptor (NMDA) such as phencyclidine (PCP) ...
AbstractSubchronic treatment with the N-methyl-d-aspartate (NMDA) antagonist phencyclidine (PCP) pro...
Subchronic treatment with the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) produces be...
Rationale N-methyl-D-aspartate receptor (NMDA-R) hypofunction has been proposed to account for the p...
Phencyclidine (PCP) is a psychotomimetic drug that elicits schizo-phrenia-like symptoms in healthy p...
Subchronic administration of PCP, a psychotomimetic agent acting as an NMDAR channel blocker, produc...
We have previously demonstrated that subchronic (five daily administrations of 2.6 mg/kg PCP) and ch...
Impaired ability to shift perceptual attentional set forms a core feature of schizophrenic illness a...
Rationale:Impaired ability to shift perceptual attentional set forms a core feature of schizophrenic...
The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamoc...
Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia...
<div><p>Antagonists of N-methyl-D-aspartate receptors (NMDAR) have psychotomimetic effects in humans...
Working memory impairment is a hallmark feature of schizophrenia and is thought be caused by dysfunc...
Repeated exposure of rats to the psychotomimetic drug phen-cyclidine (PCP) markedly increased the re...
Antagonists of N-methyl-D-aspartate receptors (NMDAR) have psychotomimetic effects in humans and are...
Non-competitive antagonists of the N-methyl-d-aspartate receptor (NMDA) such as phencyclidine (PCP) ...